Drug

D0261 | Cyclosporin A

Molecular Formula C62H111N11O12
Molecular Weight 1202.6
Structure
Trade names Neoral, Sandimmune,
Description a typical inhibitor of MPT; calcineurin inhibitor; immunosuppresant

S

L

S01XA18 Ciclosporin


[S01XA] Other ophthalmologicals


[S01X] OTHER OPHTHALMOLOGICALS


[S01] OPHTHALMOLOGICALS


[S] Sensory organs


L04AD01 Ciclosporin


[L04AD] Calcineurin inhibitors


[L04A] IMMUNOSUPPRESSANTS


[L04] IMMUNOSUPPRESSANTS


[L] Antineoplastic and immunomodulating agents


Toxicity Dose Time Species Model Method Action Positive criterion Reference
TRANSMEMBRANE POTENTIAL 40nM rat rat cortical neurons and isolated rat liver mitochondria mitochondrial membrane potential was measured in tetramethylrhodamine methyl ester (TMRM)-loaded neurons using ImageXpress MicroXL, and in rhodamine-123 loaded isolated mitochondria using a fluorescent plate reader Negative 324
DEPOLARIZATION 1 μmol/L 3 minutes rat liver mitochondria Assessment of Mitochondrial Membrane Potential; coincubated with diclofenac decrease p < 0.05 6
OPENING OF PERMEABILITY TRANSITION PORE (PTP) inhibit 248
OPENING OF PERMEABILITY TRANSITION PORE (PTP) 40nM rat liver mitochondria Assess Ca2+-mediated PT pore formation by Calcium Retention Capacity Assay (Fluo-5N fluorescence was measured in the extramitochondrial solution following repeated additions of Ca2+) inhibit half-maximal inhibition 324
OPENING OF PERMEABILITY TRANSITION PORE (PTP) 5 µM 1 hour Human HepG2 High-content screening assay Negative MEC 306
MEMBRANE POTENTIAL 5 µM 1 hour Human HepG2 High-content screening assay Increase MEC 306
MITOCHONDRIAL PARAMETERS 1 μM rat rat cortical neurons and isolated rat liver mitochondria oxygen consumption (Oroboros Oxygraph-2K) Negative 324
ACCUMULATION OF CALCIUM 1 μmol/L 2 minutes rat liver mitochondria Assessment of Mitochondrial Ca2+ Efflux; Incubated in the presence of Diclofenac(50 μmol/L); Energized with succinate Negative not mentioned 6
ATP SYNTHESIS 1 μM rat rat cortical neurons and isolated rat liver mitochondria ATP production ( Cell Titer Glo reagent) Negative 324
MITOPHAGY 5 μM mouse embryonic fibroblasts (MEFs) and SH-SY5Y cells Mitochondrial population levels were determined by flow cytometry using MitoTracker Deep Red (MTDR) dye block 252
ROS PRODUCTION 5 µM 1 hour Human HepG2 High-content screening assay Increase MEC 306

Target Dose Time Species Model Method Action Positive criterion Reference
Peptidyl-prolyl cis-trans isomerase F, mitochondrial 5 μM mouse embryonic fibroblasts (MEFs) and SH-SY5Y cells Mitochondrial population levels were determined by flow cytometry using MitoTracker Deep Red (MTDR) dye inhibitor 252
Peptidyl-prolyl cis-trans isomerase F, mitochondrial 22.5 ± 4.3nM (CypA), 1.4 ± 1.6 nM( K133I CypD) Fluorescence Polarization Assay to measure affinity of ligands to cyclophilins (fluorescein-PEG-CsA ligand as the probe) bind Ki 324
Reactive oxygen species 5 µM 1 hour Human HepG2 High-content screening assay increase MEC 306

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 403 companies from 15 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]


H350 (99.26%): May cause cancer [Danger Carcinogenicity]


H360 (97.52%): May damage fertility or the unborn child [Danger Reproductive toxicity]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


P201, P202, P264, P270, P281, P301+P312, P308+P313, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
Danger

H302: Harmful if swallowed [Warning Acute toxicity, oral]


H350: May cause cancer [Danger Carcinogenicity]


H360: May damage fertility or the unborn child [Danger Reproductive toxicity]


H362: May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]


H370: Causes damage to organs [Danger Specific target organ toxicity, single exposure]


H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]


P201, P202, P260, P263, P264, P270, P281, P301+P312, P307+P311, P308+P313, P314, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
rat LD50 intraperitoneal 147mg/kg (147mg/kg) Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 17, Pg. 365, 1986.
human TDLo oral 12mg/kg (12mg/kg) Journal of Hypertension. Vol. 11, Pg. 1209, 1993.
women TDLo oral 1911mg/kg/91W (1911mg/kg) British Journal of Rheumatology. Vol. 33, Pg. 90, 1994.
man TDLo parenteral 20mg/kg/5D-I (20mg/kg) American Journal of Ophthalmology. Vol. 126, Pg. 607, 1998.
man TDLo unreported 30mg/kg/4D-I (30mg/kg) kidney, ureter, and bladder: "changes in tubules (including acute renal failure, acute tubular necrosis)" Annals of Internal Medicine. Vol. 107, Pg. 786, 1987.
rabbit LD50 oral > 1gm/kg (1000mg/kg) Archives of Toxicology. Vol. 53, Pg. 107, 1983.
rat LD50 subcutaneous 286mg/kg (286mg/kg) Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 17, Pg. 365, 1986.
mouse LD50 intravenous 96mg/kg (96mg/kg) Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 17, Pg. 365, 1986.
mouse LD50 oral 2329mg/kg (2329mg/kg) Archives of Toxicology. Vol. 53, Pg. 107, 1983.
man TDLo oral 20mg/kg/2D-I (20mg/kg) Lancet. Vol. 2, Pg. 1092, 1986.
rat LD50 oral 1480mg/kg (1480mg/kg) Archives of Toxicology. Vol. 53, Pg. 107, 1983.
rat LD50 intravenous 24mg/kg (24mg/kg) Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 17, Pg. 365, 1986.
women TDLo oral 62500ug/kg/5D (62.5mg/kg) kidney, ureter, and bladder: other changes Lancet. Vol. 1, Pg. 1221, 1986.
man TDLo oral 14286ug/kg (14.286mg/kg) Annals of Pharmacotherpy. Vol. 34, Pg. 405, 2000.
rabbit LD50 intravenous 10mg/kg (10mg/kg) Toxicologic Pathology. Vol. 14, Pg. 73, 1986.


  • (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-((1R,2R,E)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,1 (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-((1R,2R,E)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
    (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,2 (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
    (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19 (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
    (R-(R*,R*-(E)))-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl) (R-[R*,R*-(E)])-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl) 1,11-cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(E)-(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloct-6-enoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine]
    1c5f 1cyn 2wfj
    2z6w 30-Ethyl-33-((E)-1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,28-octamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone 30-Ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
    30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone 4jjm
    5946-EP0930075A1 5946-EP2289877A1 5946-EP2292601A1
    5946-EP2292602A1 5946-EP2292603A1 5946-EP2292604A2
    5946-EP2292618A1 5946-EP2293650A1 5946-EP2298737A1
    5946-EP2298739A1 5946-EP2298740A1 5946-EP2298741A1
    5946-EP2298771A2 5946-EP2301920A1 5946-EP2301940A1
    5946-EP2308843A1 5946-EP2308861A1 59865-13-3
    79217-60-0 83HN0GTJ6D 865C133
    AB0090560 AKOS015969287 AOB2581
    AT-12519 ATH-002 Abrammune
    Antibiotic S 7481F1 Arpimune ME BDBM50022815
    BPBio1_000496 BRD-K03222093-001-01-8 BRD-K13533483-001-03-0
    BSPBio_000450 C042 C62H111N11O12
    CAS-59865-13-3 CB-01-09 MMX CCG-208184
    CCRIS 1590 CHEBI:4031 CHEBI:92233
    CHEMBL160 CS-2761 CSA
    CYA Certified Reference Material CicloMulsion
    Cicloral (antibiotic) Ciclosporin Ciclosporin (Ciclosporin A)
    Ciclosporin DT Ciclosporin [INN] Ciclosporin for system suitability, European Pharmacopoeia (EP) Reference Standard
    Ciclosporin, European Pharmacopoeia (EP) Reference Standard Ciclosporina Ciclosporina Germed
    Ciclosporina [INN-Spanish] Ciclosporine Ciclosporine [INN-French]
    Ciclosporinum Ciclosporinum [INN-Latin] Cipol N
    Cipol-N Consupren Consupren S
    CsA & IFN.alpha. Cyclo(((E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl) Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl)
    Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl) Cyclo[[(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl] Cyclokat
    Cyclosporin Cyclosporin A & IFN.alpha. Cyclosporin A, >=98.5% (TLC)
    Cyclosporin A, VETRANAL(TM), analytical standard Cyclosporin A, from Tolypocladium inflatum, >=95% (HPLC), solid Cyclosporin A, from Tolypocladium inflatum, BioReagent, for molecular biology, >=95%
    Cyclosporin-A(Cyclosporine-A) CyclosporinA Cyclosporine A
    Cyclosporine [USAN:USP] Cyclosporine, Pharmaceutical Secondary Standard Cyclosporine, United States Pharmacopeia (USP) Reference Standard
    DB00091 DE-076 DRG-0275
    DSSTox_CID_365 DSSTox_GSID_20365 DSSTox_RID_75541
    DTXSID0020365 Debio088 EBD2126862
    Equoral GTPL1024 Gengraf
    HMS1569G12 HMS2089A09 HMS2096G12
    HMS2230M14 HMS3713G12 HSDB 6881
    HY-B0579 Ikervis (opthalmic solution) Imusporin
    J10181 J90049 KS-1257
    MFCD00274558 MLS000028376 MLS001333756
    MLS002153454 MLS002207033 Mitogard
    Modusik-A NCGC00016890-01 NCGC00093704-12
    NCGC00164258-01 NCGC00164258-02 NCGC00164258-03
    NCGC00255232-01 NSC 290193 NSC290193
    Neoplanta Neoral NeuroSTAT
    Nova-22007 OL 27-400 OL-27400
    OLO-400 Optimmune PMATZTZNYRCHOR-CGLBZJNRSA-N
    Papilock Papilock Mini Prestwick2_000435
    Prestwick3_000435 Prestwick_731 Pulminiq
    Q-200913 Q367700 Ramihyphin A
    Restasis S 7481F1 S-Neoral
    SBI-0050230.P003 SCHEMBL3491 SCHEMBL4442
    SDZ-OXL 400 SMR000058578 SR-01000780563
    SR-01000780563-3 ST-603 Sandimmun
    Sandimmun Neoral Sandimmune Sandimmune Neoral
    Sang 35 Sang-2000 Sang-35
    SangCyA Seciera Sigmasporin
    Sigmasporin Microoral Tox21_110667 Tox21_110667_1
    Tox21_301849 UNII-83HN0GTJ6D Vekacia
    Verkazia (opthalmic solution) Zinograf ME Zyclorin
    cyclosporin A cyclosporine

    DrugBank Name Cyclosporine
    DrugBank DB00091
    CAS Number 104250-72-8, 55126-45-9, 59865-13-3, 79217-60-0
    PubChem Compound 5284373
    KEGG Compound ID C05086
    KEGG Drug D00184
    PubChem.Substance 46508198
    ChEBI 4031
    PharmGKB PA449167
    ChemSpider 4447449
    BindingDB 50022815.0
    TTD DAP000014
    Wikipedia Ciclosporin